By Lucas De Vries

May 19, 2020
Reading Time: < 1 minute

 

The Therapeutic Goods Administration (TGA), the Australian Department of Health’s regulator of therapeutic products, unveiled Friday a proposal to reclassify the CBD that would allow it to be sold over the counter in non-therapeutic doses. The Administration also opened a public comment period that will end next month.

Currently, CBD preparations are listed in Annex 4 and are authorized for therapeutic purposes as long as 98% of the cannabinoid content of the preparation is CBD. With the proposed changes, CBD would move to Schedule 3, no longer requiring a prescription, and as long as the following conditions apply:

  • Cannabidiol is either of plant origin or synthetic under certain conditions
  • The maximum recommended daily dose is 60 mg or less.
  • The product is presented in packages containing no more than 30 days’ supply.
  • Cannabidiol accounts for 98% or more of the total cannabinoid content of the preparation.
  • All cannabinoids, other than CBD, must be only those naturally found in cannabis and must comprise 2% or less of the total cannabinoid content of the preparation.
  • The product is intended for adults 18 years of age and older.

This proposal comes after the TGA conducted a “safety review” of CBD products. The World Health Organization (WHO) has recommended that CBD products containing no more than 0.2% THC be removed from international drug control. A vote on this WHO recommendation was expected at the March meeting of the UN Commission on Narcotic Drugs, but the vote was postponed until the December meeting.

Warning: count(): Parameter must be an array or an object that implements Countable in /home/mailmach/cbd.ci/wp-content/plugins/ultimate-author-box-lite/inc/frontend/uap-shortcode.php on line 80
style=”display:none;”>
Summary
Australia moves to over-the-counter CBD
Article Name
Australia moves to over-the-counter CBD
Description
The Therapeutic Goods Administration (TGA), the Australian Department of Health's regulator of therapeutic products, unveiled Friday a proposal to reclassify the CBD that would allow it to be sold over the counter in non-therapeutic doses.
Author
Publisher Name
CBD.CI
Publisher Logo
Spread the love
What's your reaction?
0 CommentsClose Comments

Leave a comment

escort eski┼čehir escort samsun escort gebze escort sakarya escort edirne